Targeting TRIM59 impairs RNA splicing and promotes neuroblastoma differentiation and therapeutic responses.

Clinical validation across multiple cancer cohorts reveals that elevated TRIM59 expression predicts resistance to anti-PD-1 immunotherapy, although the difference did not reach statistical significance, underscoring its role in immune evasion.

also in 111,027 other papers